Celldex Therapeutics (CLDX)Bellevue Group AG reduced its stake -2.42M shares

1.2M

Shares reported · -2.42M vs prior quarter

0.91%

Disclosed portfolio weight

$38.1M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 1, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
2. May 7, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Jun 25, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 25, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Celldex Therapeutics, Inc. (the “Company”), the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2021 Omnibus Equity Incentive Plan (the “2021 Plan”) (i) increasing the number of shares available for issuance under the 2021 Plan by 3,400,000 shares and (ii) clarifying the tax withholding…”
2. Jul 10, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.”
3. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Celldex Therapeutics

For Celldex Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CLDX page.

How this filing works

• SEC Form 13F

Other disclosures at Celldex Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 13, 2026
• SEC Form 13F-HRFeb 13, 2026

Everything OQRO holds on this company is on its CLDX page.